163 related articles for article (PubMed ID: 37732211)
1. Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA-binding proteins with prion-like domains.
Guo L; Mann JR; Mauna JC; Copley KE; Wang H; Rubien JD; Odeh HM; Lin J; Lee BL; Ganser L; Robinson E; Kim KM; Murthy AC; Paul T; Portz B; Gleixner AM; Diaz Z; Carey JL; Smirnov A; Padilla G; Lavorando E; Espy C; Shang Y; Huang EJ; Chesi A; Fawzi NL; Myong S; Donnelly CJ; Shorter J
bioRxiv; 2023 Sep; ():. PubMed ID: 37732211
[TBL] [Abstract][Full Text] [Related]
2. Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains.
Guo L; Kim HJ; Wang H; Monaghan J; Freyermuth F; Sung JC; O'Donovan K; Fare CM; Diaz Z; Singh N; Zhang ZC; Coughlin M; Sweeny EA; DeSantis ME; Jackrel ME; Rodell CB; Burdick JA; King OD; Gitler AD; Lagier-Tourenne C; Pandey UB; Chook YM; Taylor JP; Shorter J
Cell; 2018 Apr; 173(3):677-692.e20. PubMed ID: 29677512
[TBL] [Abstract][Full Text] [Related]
3. Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD.
Khalil B; Linsenmeier M; Smith CL; Shorter J; Rossoll W
Mol Neurodegener; 2024 Jan; 19(1):8. PubMed ID: 38254150
[TBL] [Abstract][Full Text] [Related]
4. FUS and TDP-43 Phases in Health and Disease.
Portz B; Lee BL; Shorter J
Trends Biochem Sci; 2021 Jul; 46(7):550-563. PubMed ID: 33446423
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of phase separation and amyloidosis of ALS/FTD-linked FUS and TDP-43.
Song J
Aging Dis; 2023 Nov; ():. PubMed ID: 38029395
[TBL] [Abstract][Full Text] [Related]
6. Phase separation and pathologic transitions of RNP condensates in neurons: implications for amyotrophic lateral sclerosis, frontotemporal dementia and other neurodegenerative disorders.
Naskar A; Nayak A; Salaikumaran MR; Vishal SS; Gopal PP
Front Mol Neurosci; 2023; 16():1242925. PubMed ID: 37720552
[TBL] [Abstract][Full Text] [Related]
7. Synaptic Paths to Neurodegeneration: The Emerging Role of TDP-43 and FUS in Synaptic Functions.
Ling SC
Neural Plast; 2018; 2018():8413496. PubMed ID: 29755516
[TBL] [Abstract][Full Text] [Related]
8. Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease.
Odeh HM; Fare CM; Shorter J
J Mol Biol; 2022 Jan; 434(1):167220. PubMed ID: 34464655
[TBL] [Abstract][Full Text] [Related]
9. RNA-binding proteins with prion-like domains in ALS and FTLD-U.
Gitler AD; Shorter J
Prion; 2011; 5(3):179-87. PubMed ID: 21847013
[TBL] [Abstract][Full Text] [Related]
10. Rapid in vitro quantification of TDP-43 and FUS mislocalisation for screening of gene variants implicated in frontotemporal dementia and amyotrophic lateral sclerosis.
Oyston LJ; Ubiparipovic S; Fitzpatrick L; Hallupp M; Boccanfuso LM; Kwok JB; Dobson-Stone C
Sci Rep; 2021 Jul; 11(1):14881. PubMed ID: 34290285
[TBL] [Abstract][Full Text] [Related]
11. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.
Ratti A; Buratti E
J Neurochem; 2016 Aug; 138 Suppl 1():95-111. PubMed ID: 27015757
[TBL] [Abstract][Full Text] [Related]
12. Loss of Dynamic RNA Interaction and Aberrant Phase Separation Induced by Two Distinct Types of ALS/FTD-Linked FUS Mutations.
Niaki AG; Sarkar J; Cai X; Rhine K; Vidaurre V; Guy B; Hurst M; Lee JC; Koh HR; Guo L; Fare CM; Shorter J; Myong S
Mol Cell; 2020 Jan; 77(1):82-94.e4. PubMed ID: 31630970
[TBL] [Abstract][Full Text] [Related]
13. Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition.
Pelaez MC; Desmeules A; Gelon PA; Glasson B; Marcadet L; Rodgers A; Phaneuf D; Pozzi S; Dutchak PA; Julien JP; Sephton CF
Acta Neuropathol Commun; 2023 Nov; 11(1):182. PubMed ID: 37974279
[TBL] [Abstract][Full Text] [Related]
14. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.
Mackenzie IR; Rademakers R; Neumann M
Lancet Neurol; 2010 Oct; 9(10):995-1007. PubMed ID: 20864052
[TBL] [Abstract][Full Text] [Related]
15. Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations.
Finelli MJ; Liu KX; Wu Y; Oliver PL; Davies KE
Hum Mol Genet; 2015 Jun; 24(12):3529-44. PubMed ID: 25792726
[TBL] [Abstract][Full Text] [Related]
16. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.
King OD; Gitler AD; Shorter J
Brain Res; 2012 Jun; 1462():61-80. PubMed ID: 22445064
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of FUS-associated ALS and FTD: insights from rodent models.
Nolan M; Talbot K; Ansorge O
Acta Neuropathol Commun; 2016 Sep; 4(1):99. PubMed ID: 27600654
[TBL] [Abstract][Full Text] [Related]
18. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells.
Colombrita C; Onesto E; Megiorni F; Pizzuti A; Baralle FE; Buratti E; Silani V; Ratti A
J Biol Chem; 2012 May; 287(19):15635-47. PubMed ID: 22427648
[TBL] [Abstract][Full Text] [Related]
19. Phase separation of RNA-binding proteins in physiology and disease: An introduction to the JBC Reviews thematic series.
Shorter J
J Biol Chem; 2019 May; 294(18):7113-7114. PubMed ID: 30948513
[TBL] [Abstract][Full Text] [Related]
20. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.
Mann JR; Gleixner AM; Mauna JC; Gomes E; DeChellis-Marks MR; Needham PG; Copley KE; Hurtle B; Portz B; Pyles NJ; Guo L; Calder CB; Wills ZP; Pandey UB; Kofler JK; Brodsky JL; Thathiah A; Shorter J; Donnelly CJ
Neuron; 2019 Apr; 102(2):321-338.e8. PubMed ID: 30826182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
